Literature DB >> 17489504

Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine.

Jun Yang1, Anto Satriyo Nugroho, Kazunobu Yamauchi, Kentaro Yoshioka, Jiang Zheng, Kai Wang, Ken Kato, Susumu Kuroyanagi, Akira Iwata.   

Abstract

Chronic hepatitis C is a disease that is difficult to treat. At present, interferon might be the only drug, which can cure this kind of disease, but its efficacy is limited and patients face the risk of side effects and high expense, so doctors considering interferon must make a serious choice. The purpose of this study is to establish a simple model and use the clinical data to predict the interferon efficacy. This model is a combination of Feature Subset Selection and the Classifier using a Support Vector Machine (SVM). The study indicates that when five features have been selected, the identification by the SVM is as follows: the identification rate for the effective group is 85%, and the ineffective group 83%. Analysis of selected features show that HCV-RNA level, hepatobiopsy, HCV genotype, ALP and CHE are the most significant features. The results thus serve for the doctors' reference when they make decisions regarding interferon treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17489504     DOI: 10.1007/s10916-006-9046-8

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  25 in total

1.  Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.

Authors:  K Kanai; M Kako; T Aikawa; T Kumada; T Kawasaki; T Hatahara; Y Oka; M Mizokami; T Sakai; K Iwata
Journal:  Liver       Date:  1995-08

2.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.

Authors:  Masahiko Takahashi; Hidetsugu Saito; Makiko Higashimoto; Kazuhiro Atsukawa; Hiromasa Ishii
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

Authors:  J Y Lau; G L Davis; J Kniffen; K P Qian; M S Urdea; C S Chan; M Mizokami; P D Neuwald; J C Wilber
Journal:  Lancet       Date:  1993-06-12       Impact factor: 79.321

7.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha.

Authors:  H Hagiwara; N Hayashi; E Mita; K Ueda; T Takehara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

View more
  1 in total

1.  [International outcomes from attempts to implement a clinical decision support system in gastroenterology].

Authors:  Josceli Maria Tenório; Anderson Diniz Hummel; Vera Lucia Sdepanian; Ivan Torres Pisa; Heimar de Fátima Marin
Journal:  J Health Inform       Date:  2011 Jan-Mar
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.